Aurora Private Wealth Inc. Has $24.99 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Aurora Private Wealth Inc. lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 4,627.2% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 30,254 shares of the company’s stock after acquiring an additional 29,614 shares during the period. Eli Lilly and Company makes up approximately 0.7% of Aurora Private Wealth Inc.’s investment portfolio, making the stock its 22nd largest position. Aurora Private Wealth Inc.’s holdings in Eli Lilly and Company were worth $24,987,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Mascagni Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at about $43,000. Prudent Man Investment Management Inc. acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at about $48,000. Highline Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 53.3% in the first quarter. Highline Wealth Partners LLC now owns 69 shares of the company’s stock valued at $57,000 after acquiring an additional 24 shares in the last quarter. Capital A Wealth Management LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at about $63,000. Finally, Bellwether Advisors LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at about $66,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 1.8%

Shares of NYSE LLY opened at $792.41 on Thursday. The company has a 50 day simple moving average of $782.41 and a 200 day simple moving average of $800.16. The firm has a market cap of $751.00 billion, a PE ratio of 64.48, a price-to-earnings-growth ratio of 1.14 and a beta of 0.40. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.58 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.76%. Eli Lilly and Company’s payout ratio is 48.82%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on LLY. Wells Fargo & Company reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price objective on the stock. Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Saturday, June 7th. UBS Group reduced their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. Finally, Hsbc Global Res downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,011.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.